标题
EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
作者
关键词
-
出版物
Frontiers in Oncology
Volume 9, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2019-10-11
DOI
10.3389/fonc.2019.01044
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Towards the first targeted therapy for triple-negative breast cancer: Repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor
- (2019) Kamal Ahmed et al. CANCER LETTERS
- Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma
- (2019) Daniel R. McGowan et al. EUROPEAN JOURNAL OF CANCER
- A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
- (2019) R.K. Kelley et al. Clinical and Translational Gastroenterology
- A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients
- (2019) Tetsuo Tani et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors
- (2018) Nithya Krishnamurthy et al. CANCER TREATMENT REVIEWS
- Strategies to target the Hedgehog signaling pathway for cancer therapy
- (2018) Minhang Xin et al. MEDICINAL RESEARCH REVIEWS
- Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI
- (2018) Chien-Hui Weng et al. ONCOGENE
- A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non–small cell lung cancer
- (2017) Jean-Charles Soria et al. EUROPEAN JOURNAL OF CANCER
- Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
- (2017) David Planchard et al. LANCET ONCOLOGY
- IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights
- (2017) Heming Li et al. Molecular Cancer
- JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer
- (2017) Kazuhiko Shien et al. MOLECULAR CANCER THERAPEUTICS
- EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
- (2017) Tsukasa Shibue et al. Nature Reviews Clinical Oncology
- Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
- (2017) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC
- (2017) Mark J. McKeage et al. Targeted Oncology
- IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells
- (2017) Dianna Hussmann et al. Oncotarget
- Non-coding RNAs as emerging regulators of epithelial to mesenchymal transition in non-small cell lung cancer
- (2017) Ying Chen et al. Oncotarget
- Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
- (2017) Carminia Maria Della Corte et al. Oncotarget
- Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features
- (2017) Hiroki Sato et al. Scientific Reports
- Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine
- (2017) Chiranjib Chakraborty et al. Molecular Therapy-Nucleic Acids
- Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c
- (2017) Michiko Narita et al. PLoS One
- Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells
- (2017) An-Fu Lee et al. PLoS One
- Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer
- (2016) Michael Bergqvist et al. ACTA ONCOLOGICA
- TMPRSS4 induces cancer stem cell-like properties in lung cancer cells and correlates with ALDH expression in NSCLC patients
- (2016) Arrate L. de Aberasturi et al. CANCER LETTERS
- Molecular mechanisms of microRNAs in regulating epithelial–mesenchymal transitions in human cancers
- (2016) Jinlong Tang et al. CANCER LETTERS
- Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
- (2016) Hironobu Minami et al. CANCER SCIENCE
- EMT: Matter of Life or Death?
- (2016) Sonal Gupta et al. CELL
- TGF-β Tumor Suppression through a Lethal EMT
- (2016) Charles J. David et al. CELL
- EMT: 2016
- (2016) M. Angela Nieto et al. CELL
- A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer
- (2016) Shubham Pant et al. EUROPEAN JOURNAL OF CANCER
- Approaches for targeting cancer stem cells drug resistance
- (2016) Roberta Rosa et al. Expert Opinion on Drug Discovery
- Drug-resistant CXCR4-positive cells have the molecular characteristics of EMT in NSCLC
- (2016) Hanlu Yin et al. GENE
- Repression of Smad4 by miR-205 moderates TGF-β-induced epithelial-mesenchymal transition in A549 cell lines
- (2016) Yuanyuan Zeng et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer
- (2016) Noboru Yamamoto et al. INVESTIGATIONAL NEW DRUGS
- miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance
- (2016) Merve Mutlu et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Hsa-miR-1246 and hsa-miR-1290 are associated with stemness and invasiveness of non-small cell lung cancer
- (2016) Gwangil Kim et al. LUNG CANCER
- Cigarette smoke extract exposure induces EGFR-TKI resistance in EGFR-mutated NSCLC via mediating Src activation and EMT
- (2016) Dandan Li et al. LUNG CANCER
- Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications
- (2016) Silvia Juliana Serrano-Gomez et al. Molecular Cancer
- Epithelial–mesenchymal transition: a new target in anticancer drug discovery
- (2016) Fabrizio Marcucci et al. NATURE REVIEWS DRUG DISCOVERY
- HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma
- (2016) ZHIHAO WANG et al. ONCOLOGY REPORTS
- Concise Review: Stem Cells and Epithelial-Mesenchymal Transition in Cancer: Biological Implications and Therapeutic Targets
- (2016) Ryo Sato et al. STEM CELLS
- EGFR as a Pharmacological Target in EGFR -Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?
- (2016) E-->-E -->Ke et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- A genetic cell context-dependent role for ZEB1 in lung cancer
- (2016) Ting Zhang et al. Nature Communications
- Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines
- (2016) Xiao-Yan Bai et al. PLoS One
- ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- (2016) Takeshi Yoshida et al. PLoS One
- Requirement of HDAC6 for activation of Notch1 by TGF-β1
- (2016) Brian Deskin et al. Scientific Reports
- Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies
- (2015) A. L. Wong et al. ANNALS OF ONCOLOGY
- Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
- (2015) C. Zhou et al. ANNALS OF ONCOLOGY
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors
- (2015) Yutaka Fujiwara et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Notch signaling: An emerging therapeutic target for cancer treatment
- (2015) Xun Yuan et al. CANCER LETTERS
- Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition
- (2015) M. Soucheray et al. CANCER RESEARCH
- Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib
- (2015) Shinsuke Hashida et al. CANCER SCIENCE
- SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer
- (2015) C. M. Della Corte et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade
- (2015) W. T. Iams et al. CLINICAL CANCER RESEARCH
- A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors
- (2015) E. G. Chiorean et al. CLINICAL CANCER RESEARCH
- A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer
- (2015) T. K. Owonikoko et al. CLINICAL CANCER RESEARCH
- Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non-Small Cell Lung Cancer
- (2015) V. K. Anagnostou et al. CLINICAL CANCER RESEARCH
- A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer
- (2015) G. Giaccone et al. EUROPEAN JOURNAL OF CANCER
- Targeting microRNAs in epithelial-to-mesenchymal transition-induced cancer stem cells: therapeutic approaches in cancer
- (2015) Minal Garg EXPERT OPINION ON THERAPEUTIC TARGETS
- Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer
- (2015) David E. Gerber et al. LUNG CANCER
- Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations
- (2015) Chang Dong Yeo et al. LUNG CANCER
- A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer
- (2015) Georg Holgersson et al. MEDICAL ONCOLOGY
- Targeting Notch, Hedgehog and Wnt pathways in cancer stem cells: clinical update
- (2015) Naoko Takebe et al. Nature Reviews Clinical Oncology
- Targeting the WNT Signaling Pathway in Cancer Therapeutics
- (2015) D. Tai et al. ONCOLOGIST
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
- (2015) David Hong et al. Science Translational Medicine
- Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches
- (2015) Qin Pan et al. STEM CELLS
- Epithelial–Mesenchymal Plasticity: A Central Regulator of Cancer Progression
- (2015) Xin Ye et al. TRENDS IN CELL BIOLOGY
- Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors
- (2015) Ashvinikumar V. Gavai et al. ACS Medicinal Chemistry Letters
- Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
- (2015) Michael Lahn et al. Drug Design Development and Therapy
- Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer
- (2015) Juan Zhou et al. Oncotarget
- IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer
- (2015) Yi-Nan Liu et al. Oncotarget
- Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells
- (2015) Ryo Yamashita et al. Cancer Medicine
- Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer
- (2014) G. V. Scagliotti et al. ANNALS OF ONCOLOGY
- Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study
- (2014) Richard J. Kovacs et al. Cardiovascular Toxicology
- A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors
- (2014) A. J. Wagner et al. CLINICAL CANCER RESEARCH
- A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors
- (2014) J. E. Gray et al. CLINICAL CANCER RESEARCH
- Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors
- (2014) J. Goldman et al. CLINICAL CANCER RESEARCH
- First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
- (2014) D. Sarker et al. CLINICAL CANCER RESEARCH
- A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral -Secretase Inhibitor PF-03084014
- (2014) W. A. Messersmith et al. CLINICAL CANCER RESEARCH
- A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
- (2014) E. Angevin et al. CLINICAL CANCER RESEARCH
- Metformin Sensitizes EGFR-TKI-Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal
- (2014) L. Li et al. CLINICAL CANCER RESEARCH
- Signaling pathway cooperation in TGF-β-induced epithelial–mesenchymal transition
- (2014) Rik Derynck et al. CURRENT OPINION IN CELL BIOLOGY
- A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors
- (2014) Noelle K. LoConte et al. INVESTIGATIONAL NEW DRUGS
- Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
- (2014) Jordi Rodón et al. INVESTIGATIONAL NEW DRUGS
- Randomized, Phase III Trial of First-Line Figitumumab in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Advanced Non–Small-Cell Lung Cancer
- (2014) Corey J. Langer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
- (2014) L Molife et al. Journal of Hematology & Oncology
- Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application
- (2014) Xun Yuan et al. Journal of Hematology & Oncology
- Tackling the cancer stem cells — what challenges do they pose?
- (2014) Diwakar R. Pattabiraman et al. NATURE REVIEWS DRUG DISCOVERY
- Therapeutic modulation of Notch signalling — are we there yet?
- (2014) Emma R. Andersson et al. NATURE REVIEWS DRUG DISCOVERY
- Molecular mechanisms of epithelial–mesenchymal transition
- (2014) Samy Lamouille et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- ERK1/2 Blockade Prevents Epithelial-Mesenchymal Transition in Lung Cancer Cells and Promotes Their Sensitivity to EGFR Inhibition
- (2013) J. M. Buonato et al. CANCER RESEARCH
- Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo
- (2013) Mian Xie et al. EUROPEAN JOURNAL OF CANCER
- MicroRNAs and other non-coding RNAs as targets for anticancer drug development
- (2013) Hui Ling et al. NATURE REVIEWS DRUG DISCOVERY
- The mechanisms of Hedgehog signalling and its roles in development and disease
- (2013) James Briscoe et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs
- (2010) Jin-Haeng Chung et al. LUNG CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now